Abstract:Chimeric antigen receptor (CAR) T cell therapies have transformed outcomes for many patients with hematological malignancies. However, some patients do not respond to CAR T cell treatment, and adapting CAR T cells for solid and brain tumors has been met with many challenges including a hostile tumor microenvironment and poor CAR T cell persistence. Thus, it is unlikely that CAR T cell therapy alone will be sufficient for consistent, complete tumor clearance across cancer patients. Combinatorial therapies of CAR T cells and chemotherapeutics are a promising approach for overcoming this as chemotherapeutics could augment CAR T cells for improved anti-tumor activity or work in tandem with CAR T cells to clear tumors. Herein, we review efforts towards achieving successful CAR T cell and chemical drug combination therapies. We focus on combination therapies with approved chemotherapeutics as these will be more easily translated to the clinic, but also review non-approved chemotherapeutics and drug screens designed to reveal promising new CAR T cell and chemical drug combinations. Together, this review highlights the promise of CAR T cell and chemotherapy combinations with specific focus on how combinatorial therapy overcomes challenges faced by either monotherapy and supports the potential of this therapeutic strategy to improve outcomes for cancer patients. Significance Statement Improving currently available CAR T cell products via combinatorial therapy with chemotherapeutics has the potential to drastically expand the types of cancers and number of patients that could benefit from these therapies when neither alone has been sufficient to achieve tumor clearance. Herein, we provide a thorough review of the current efforts towards studying CAR T and chemotherapy combinatorial therapies and provide perspectives on optimal ways to identify new and effective combinations moving forward.

CAR-T cell combination therapies in hematologic malignancies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

Advances in CAR-T-cell therapy in T-cell malignancies

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors

CAR T-cell Immunotherapy: a Powerful Weapon for Fighting Hematological B-cell Malignancies

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Combining chemotherapy with CAR-T cell therapy in treating solid tumors

Therapeutic advantage of combinatorial CAR T cell and chemo-therapies

Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Current progress in CAR-T cell therapy for tumor treatment

Current state of CAR-T therapy for T-cell malignancies

Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies